All Institutions
Search all resources
Search for entire words only

BIA 9 - 1067 (Opicapone)

BIAL - Portela & Cª, S.A.
Project classification

Scientific area

3.1 Basic medicine


Neurosciences (including psychophysiology)

Project description

Project title

BIA 9 - 1067 (Opicapone)

Scientific Coordinator's name:

Prof. Patrício Soares-da-Silva

Scientific Coordinator's e-mail:

Principal R&D Unit:

Prof. Patrício Soares-da-Silva

Other R&D Units involved in the project:

Other R&D units involved in the project

Project keyword(s)

BIA 9-1067, Opicapone, Parkinson Disease, COMT, Levodopa

Short abstract and comments

Opicapone (BIA 9-1067) is currently under developed by BIAL (Portela & Cª, S.A.) to be used in combination with levodopa/carbidopa or levodopa/benserazide preparations in Parkinson’s disease (PD) patients. BIA 9-1067 is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor that increases levodopa plasma levels when co-administered with levodopa and a peripheral dopa decarboxylase inhibitor (DDCI).

Potential uses/indications

Parkinson Disease



Partner Status: Seeking Partners?


Grant number (QREN, FP7, Eureka, etc)

QREN 4584

Last edited on

2011-11-09 14:21:17

Health Cluster Portugal All rights reserved
© 2024 Health Cluster Portugal All rights reserved